person · Reporting owner
O'Farrell Elizabeth G.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GERON CORPGERN · Entity 4989 | Director | May 20, 2026 | May 26, 2026 |
| Inhibikase Therapeutics, Inc.IKT · Entity 5838 | Director | June 24, 2022 | June 29, 2022 |
| LENSAR, Inc.LNSR · Entity 6733 | Director | June 03, 2026 | June 05, 2026 |
| PDL BIOPHARMA, INC.PDLI · Entity 143144 | Director | November 23, 2020 | November 25, 2020 |
| SpyGlass Pharma, Inc.SGP · Entity 5034 | Director | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GERON CORP
Report date May 20, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-05-19 | Direct | 220,000 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 220,000 · Balance 220,000 F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.
Inhibikase Therapeutics, Inc.
Report date June 24, 2022 · Filed June 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.81 · Expires 2029-06-24 | Direct | 40,000 |
Reported balance
After 2022-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-24 · Grant · Acquired 40,000 · Balance 40,000 F1: This entire stock option grant will vest 100% in a single tranche on the earlier of June 24, 2023 or the day prior to the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This entire stock option grant will vest 100% in a single tranche on the earlier of June 24, 2023 or the day prior to the next annual meeting of stockholders.
LENSAR, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,368 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,421 · Balance 67,368 F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
PDL BIOPHARMA, INC.
Report date November 23, 2020 · Filed November 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-23 transaction · row 1
1 source rowRow 1 · 2020-11-23 · Sale · Disposed 25,826 · Balance 0 |
SpyGlass Pharma, Inc.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-05 | Direct | 13,700 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 13,700 · Balance 13,700 F1: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean February 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean February 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 21:31 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 17,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-259993 · ownership.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,368 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 20, 2026 Filed May 26, 2026 23:45 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001744662-26-000006 · form4-05262026_070508.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2036-05-19 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:46 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | GrantStock Option (right to buy) · Derivative | 13,700 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001744662-26-000004 · form4-02092026_090256.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2036-02-05 F1 · derivative.exercise_date: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean February 5, 2026. Read SEC document |
| May 23, 2025 Filed May 28, 2025 20:30 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 7,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-078372 · ownership.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,947 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 23, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:01 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0000886744-25-000022 · wk-form4_1747947705.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-05-20 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. Read SEC document |
| May 09, 2024 Filed May 10, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-24-057794 · ownership.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-05-08 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:30 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-057104 · ownership.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,573 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 7, 2025, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 00:52 UTC | GERON CORP GERN · Entity 4989 | PurchaseCommon Stock | 6,579 | $2.28 | $15,000.12 |
DisclosureSEC source: 0001062993-23-017095 · form4.xml · nonDerivative · entry 2 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 26,220 Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 00:52 UTC | GERON CORP GERN · Entity 4989 | PurchaseCommon Stock | 6,607 | $2.28 | $15,063.96 |
DisclosureSEC source: 0001062993-23-017095 · form4.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,407 Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:35 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001062993-23-012821 · form4.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:01 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 33,175 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0000899243-23-014077 · doc4.xml · derivative · entry 2 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,175 Underlying: Common Stock · 33,175 shares Expires 2033-05-25 F2 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:01 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 9,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014077 · doc4.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,573 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2024, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| June 24, 2022 Filed Jun 29, 2022 01:00 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001209191-22-039709 · doc4.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: This entire stock option grant will vest 100% in a single tranche on the earlier of June 24, 2023 or the day prior to the next annual meeting of stockholders. Read SEC document |
| May 25, 2022 Filed May 28, 2022 01:24 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 15,616 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020053 · doc4.xml · derivative · entry 2 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,616 Underlying: Common Stock · 15,616 shares Expires 2032-05-25 F3 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 25, 2022 Filed May 28, 2022 01:24 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 4,285 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020053 · doc4.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,285 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2023, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. F2 · balance_after: Includes 7,000 shares of the Issuer's common stock inadvertently omitted from the Reporting Person's original Form 3. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:17 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001062993-22-012159 · form4.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-05-09 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 23:12 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 22,677 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-21-086991 · tm2120992d4_4.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,677 Underlying: Common Stock · 22,677 shares Expires 2028-06-25 Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:15 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 20,847 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0000899243-21-020142 · doc4.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,847 Underlying: Common Stock · 20,847 shares Expires 2031-05-18 F1 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 18, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 11, 2021 Filed May 14, 2021 01:25 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000886744-21-000040 · edgar.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2031-05-10 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:13 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 13,445 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0000899243-21-011935 · doc4.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,445 Underlying: Common Stock · 13,445 shares Expires 2031-03-12 F1 · derivative.exercise_date: The option vests as to one-third of the award on February 1, 2022 and, as to the remaining amount of the award, in twenty-four (24) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:10 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 28,249 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0000899243-21-004176 · doc4.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,249 Underlying: Common Stock · 28,249 shares Expires 2031-02-01 F1 · derivative.exercise_date: The option vests as to one-third of the award on February 1, 2022 and, as to the remaining amount of the award, in twenty-four (24) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| December 22, 2020 Filed Dec 30, 2020 02:53 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 6,825 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140311 · tm2039455d5_form4.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,825 Underlying: Common Stock · 6,825 shares Expires 2030-12-22 Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 00:25 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | SaleCommon stock | 25,826 | $2.44 | $63,015.44 |
DisclosureSEC source: 0000882104-20-000193 · wf-form4_160626392267698.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 18, 2020 Filed Nov 21, 2020 01:22 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | SaleCommon stock | 63,291 | $2.38 | $150,695.87 |
DisclosureSEC source: 0000882104-20-000189 · wf-form4_160592174040723.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,826 Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 00:57 UTC | GERON CORP GERN · Entity 4989 | PurchaseCommon Stock | 17,441 | $1.73 | $30,172.93 |
DisclosureSEC source: 0000886744-20-000058 · edgar.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 19,641 Read SEC document |
| August 19, 2020 Filed Aug 24, 2020 10:05 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 118,671 | $3.63 Strike: $3.63 | $430,775.73 |
DisclosureSEC source: 0000882104-20-000136 · wf-form4_159826352423933.xml · derivative · entry 2 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,671 Underlying: Common stock · 118,671 shares Expires 2030-08-19 F2 · derivative.exercise_date: The stock options will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date. Read SEC document |
| August 19, 2020 Filed Aug 24, 2020 10:05 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 25,826 | $0.00 | $0.00 |
DisclosureSEC source: 0000882104-20-000136 · wf-form4_159826352423933.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,117 F1 · shares: The restricted stock will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:14 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000886744-20-000051 · edgar.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 02:10 UTC | GERON CORP GERN · Entity 4989 | PurchaseCommon Stock | 2,200 | $1.34 | $2,948.00 |
DisclosureSEC source: 0000886744-20-000008 · edgar.xml · nonDerivative · entry 2 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,200 Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 02:10 UTC | GERON CORP GERN · Entity 4989 | PurchaseCommon Stock | 800 | $1.35 | $1,080.00 |
DisclosureSEC source: 0000886744-20-000008 · edgar.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Read SEC document |
| June 20, 2019 Filed Jun 25, 2019 01:37 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 126,050 | $3.00 Strike: $3.00 | $378,150.00 |
DisclosureSEC source: 0000882104-19-000070 · wf-form4_156142662617861.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,050 Underlying: Common stock · 126,050 shares Expires 2029-06-19 F1 · derivative.exercise_date: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 23:24 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000886744-19-000064 · edgar.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| March 26, 2019 Filed Mar 29, 2019 00:24 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0000886744-19-000042 · edgar.xml · derivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-03-25 F1 · derivative.exercise_date: This option vests in a series of three equal consecutive annual installments commencing from March 26, 2019, subject to the non-employee director providing continuous service to the Company through each vesting date. Read SEC document |
| June 22, 2018 Filed Jun 25, 2018 20:10 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 63,291 | $2.37 | $149,999.67 |
DisclosureSEC source: 0000882104-18-000080 · wf-form4_152995743955623.xml · nonDerivative · entry 1 O'Farrell Elizabeth G. · CIK 0001744662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,291 F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distributions will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribution to all stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.